Mergers & Acquisitions

3 Simple Reasons I like TG Therapeutics Inc (NASDAQ:TGTX) Stock Long-Term

By: Brian Nichols - 05/30/2017 2:43 AM

As an investor, I’d much rather see TGTX stock near 52-week highs of $15/share vs $11/share. However, I don’t consider it bothersome that TG Therapeutics Inc (NASDAQ:TGTX) has been volatile since its its announcement of positive results from a Phase 3 clinical trial, GENUINE, assessing TG-1101 (ublituximab) and ibrutinib (AbbVie’s (NYSE:ABBV) Imbruvica) in treatment-experienced high-risk chronic lymphocytic leukemia (CLL) patients.

Posted in: Editor's Pick, Healthcare & Biotech, Members
  Comments: 1

3 Simple Reasons I like TG Therapeutics Inc (NASDAQ:TGTX) Stock Long-Term

By: Brian Nichols - 05/30/2017 2:43 AM

As an investor, I’d much rather see TGTX stock near 52-week highs of $15/share vs $11/share. However, I don’t consider it bothersome that TG Therapeutics Inc (NASDAQ:TGTX) has been volatile since its its announcement of positive results from a Phase 3 clinical trial, GENUINE, assessing TG-1101 (ublituximab) and ibrutinib (AbbVie’s (NYSE:ABBV) Imbruvica) in treatment-experienced high-risk chronic lymphocytic leukemia (CLL) patients.

Posted in: Editor's Pick, Healthcare & Biotech, Members
  Comments: 1

3 Simple Reasons I like TG Therapeutics Inc (NASDAQ:TGTX) Stock Long-Term

By: Brian Nichols - 05/30/2017 2:43 AM

As an investor, I’d much rather see TGTX stock near 52-week highs of $15/share vs $11/share. However, I don’t consider it bothersome that TG Therapeutics Inc (NASDAQ:TGTX) has been volatile since its its announcement of positive results from a Phase 3 clinical trial, GENUINE, assessing TG-1101 (ublituximab) and ibrutinib (AbbVie’s (NYSE:ABBV) Imbruvica) in treatment-experienced high-risk chronic lymphocytic leukemia (CLL) patients.

Posted in: Editor's Pick, Healthcare & Biotech, Members
  Comments: 1

3 Simple Reasons I like TG Therapeutics Inc (NASDAQ:TGTX) Stock Long-Term

By: Brian Nichols - 05/30/2017 2:43 AM

As an investor, I’d much rather see TGTX stock near 52-week highs of $15/share vs $11/share. However, I don’t consider it bothersome that TG Therapeutics Inc (NASDAQ:TGTX) has been volatile since its its announcement of positive results from a Phase 3 clinical trial, GENUINE, assessing TG-1101 (ublituximab) and ibrutinib (AbbVie’s (NYSE:ABBV) Imbruvica) in treatment-experienced high-risk chronic lymphocytic leukemia (CLL) patients.

Posted in: Editor's Pick, Healthcare & Biotech, Members
  Comments: 1

3 Simple Reasons I like TG Therapeutics Inc (NASDAQ:TGTX) Stock Long-Term

By: Brian Nichols - 05/30/2017 2:43 AM

As an investor, I’d much rather see TGTX stock near 52-week highs of $15/share vs $11/share. However, I don’t consider it bothersome that TG Therapeutics Inc (NASDAQ:TGTX) has been volatile since its its announcement of positive results from a Phase 3 clinical trial, GENUINE, assessing TG-1101 (ublituximab) and ibrutinib (AbbVie’s (NYSE:ABBV) Imbruvica) in treatment-experienced high-risk chronic lymphocytic leukemia (CLL) patients.

Posted in: Editor's Pick, Healthcare & Biotech, Members
  Comments: 1

3 Simple Reasons I like TG Therapeutics Inc (NASDAQ:TGTX) Stock Long-Term

By: Brian Nichols - 05/30/2017 2:43 AM

As an investor, I’d much rather see TGTX stock near 52-week highs of $15/share vs $11/share. However, I don’t consider it bothersome that TG Therapeutics Inc (NASDAQ:TGTX) has been volatile since its its announcement of positive results from a Phase 3 clinical trial, GENUINE, assessing TG-1101 (ublituximab) and ibrutinib (AbbVie’s (NYSE:ABBV) Imbruvica) in treatment-experienced high-risk chronic lymphocytic leukemia (CLL) patients.

Posted in: Editor's Pick, Healthcare & Biotech, Members
  Comments: 1